Share on StockTwits

St. Jude Medical (NYSE:STJ)‘s stock had its “neutral” rating restated by Zacks in a research report issued to clients and investors on Monday. They currently have a $74.00 price objective on the stock. Zacks‘s price objective indicates a potential upside of 5.52% from the company’s current price.

Zacks’ analyst wrote, “St. Jude’s 2014-first quarter adjusted earnings per share rose 4.3% to $0.96 and beat the Zacks Consensus Estimate by a penny. Revenues increased a meager 2.0% and also exceeded the mark. The company’s upgraded guidance for full year 2014 is encouraging. Strong international growth should continue to aid overall revenue growth for the company. However, St. Jude faces increased competitive and pricing pressures, as well as currency fluctuations and other macroeconomic headwinds. Therefore, we reiterate our Neutral recommendation on St. Jude and set a price target of $74.00.”

STJ has been the subject of a number of other recent research reports. Analysts at Wells Fargo & Co. reiterated an “average” rating on shares of St. Jude Medical in a research note on Thursday, May 29th. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of St. Jude Medical in a research note on Friday, May 9th. They now have a $75.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated a “sell” rating on shares of St. Jude Medical in a research note on Monday, April 21st. They now have a $53.00 price target on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $66.00.

St. Jude Medical (NYSE:STJ) traded up 1.10% during mid-day trading on Monday, hitting $70.90. The stock had a trading volume of 2,477,050 shares. St. Jude Medical has a 52-week low of $45.82 and a 52-week high of $70.59. The stock’s 50-day moving average is $66.44 and its 200-day moving average is $64.78. The company has a market cap of $20.152 billion and a P/E ratio of 27.28.

St. Jude Medical (NYSE:STJ) last announced its earnings results on Wednesday, April 16th. The company reported $0.96 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.95 by $0.01. The company had revenue of $1.36 million for the quarter, compared to the consensus estimate of $1.36 million. During the same quarter in the prior year, the company posted $0.92 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Analysts expect that St. Jude Medical will post $3.99 EPS for the current fiscal year.

St. Jude Medical, Inc (NYSE:STJ) develops, manufactures and distributes cardiovascular medical devices.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.